Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 20/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8971145 | 0.83 | SLC6A4 (0.51) | SLC6A9 | |
| Fumaric Acid SCHEMBL9445703 | 0.82 | SLC6A9 (0.47) | SLC6A9 | |
| SCHEMBL15127607 | 0.81 | SLC6A9 (1.00) | SLC6A9ALDH1A1CYP2D6MAPTCYP2C9 | |
| SCHEMBL1171367 | 0.81 | SLC6A9 (1.00) | SLC6A9ALDH1A1CYP2D6MAPTCYP2C9 | |
| SCHEMBL8971666 | 0.81 | SLC6A4 (0.49) | SLC6A9ALDH1A1CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL6259387 | 0.80 | SLC6A9 (0.72) | SLC6A9ALDH1A1CYP2D6MAPTCYP2C9 | |
| SCHEMBL8971243 | 0.79 | SLC6A9 (0.44) | SLC6A9 | |
| SCHEMBL6826726 | 0.78 | SLC6A9 (0.55) | SLC6A9ALDH1A1CYP2D6MAPTCYP2C9 | |
| SCHEMBL6567420 | 0.78 | SLC6A9 (0.93) | SLC6A9ALDH1A1CYP2D6MAPTCYP2C9 | |
| SCHEMBL6254425 | 0.78 | SLC6A9 (0.85) | SLC6A9ALDH1A1CYP2D6MAPTCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020219975-A1 | COMPOSITIONS FOR IMPROVING BRAIN HEALTH AND MEMORY | CYTOSOLVE, INC. (US) | 2020-10-29 | — | — | WO | claimed |
| WO-2006034196-A1 | COMPOSITIONS FOR ENHANCING MEMORY AND METHODS THEREFOR | LIFELIKE BIOMATIC INC. (US) | 2006-03-30 | — | — | WO | claimed |
| US-20060063707-A1 | Compositions for enhancing memory and methods therefor | LIFELIKE BIOMATIC, INC. (US) | 2006-03-23 | — | — | US | claimed |
| US-20220117284-A1 | Compositions for Improving Low Testosterone Levels | CYTOSOLVE, INC. | 2022-04-21 | — | — | US | disclosed |
| WO-2020219975-A1 | COMPOSITIONS FOR IMPROVING BRAIN HEALTH AND MEMORY | CYTOSOLVE, INC. (US) | 2020-10-29 | — | — | WO | disclosed |
| EP-2288345-B1 | PSYCHO-PHARMACEUTICALS | UNIV DUBLIN (IE) | 2015-06-10 | — | — | EP | disclosed |
| WO-2011067225-A1 | COMPOSITIONS TARGETING CB1 RECEPTOR FOR CONTROLLING FOOD INTAKE | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2011-06-09 | — | — | WO | disclosed |
| EP-2288345-A1 | PSYCHO-PHARMACEUTICALS | University College Dublin National University Of Ireland, Dublin (IE) | 2011-03-02 | — | — | EP | disclosed |
| US-20110034565-A1 | PSYCHO-PHARMACEUTICALS | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2011-02-10 | — | — | US | disclosed |
| WO-2009128058-A1 | PSYCHO-PHARMACEUTICALS | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al (IE) | 2009-10-22 | — | — | WO | disclosed |
| WO-2006034196-A1 | COMPOSITIONS FOR ENHANCING MEMORY AND METHODS THEREFOR | LIFELIKE BIOMATIC INC. (US) | 2006-03-30 | — | — | WO | disclosed |
| US-20060063707-A1 | Compositions for enhancing memory and methods therefor | LIFELIKE BIOMATIC, INC. (US) | 2006-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063707-A1 | Compositions for enhancing memory and methods therefor | GRIN1, GRIN3A, GRIN2A | SLC6A9 2144/4885ALDH1A1 4321/4885CYP2D6 4863/4885 |
| US-20110034565-A1 | PSYCHO-PHARMACEUTICALS | PNMT, HTR3C, HTR5A | SLC6A9 3575/4885ALDH1A1 2279/4885CYP2D6 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.